Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers

Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute

CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Columns

Q&A column

March 2026
Q. How should a blood bank respond when a non-irradiated blood product is inadvertently transfused to a patient who requires irradiated components, and what steps must be taken to ensure patient safety and regulatory compliance? Read answer.

Q. We are using direct smears for nongynecologic fine-needle aspirations and thinking about switching to liquid-based cytology (SurePath) preparation. There is nothing in the CAP accreditation checklist that pertains to a switch in slide preparation method… Read answer.

Put It on the Board

March 2026—The College of American Pathologists (CAP) emphasizes the complementary role of AI in pathology, highlighting the need for local pathologists to evaluate AI system performance.

Letters

March 2026—Pathologists’ assistants (PAs) are vital to pathology practice, but there is room for improvement in collaboration with pathologists.

From the President’s Desk

February 2026—The pathology community must embrace new technologies, such as digital pathology and AI, to avoid being left behind.

Clinical pathology selected abstracts

February 2026—A study of 42 thrombocytopenic neonates found that platelet transfusions increased platelet counts but did not significantly impact bleeding. Another study investigated the impact of probiotics on gut microbiota after colonoscopy.

Anatomic pathology selected abstracts

February 2026—A study introduced a computational framework to analyze collagen disorder architectural (CoDA) features in colon cancer patients, revealing significant associations with clinical, molecular, and genetic factors. Additionally, a dedicated histopathologic assessment of rituximab-associated CVID-like enteropathy highlighted key histologic features, emphasizing the importance of pathologist awareness of this entity.

Molecular pathology selected abstracts

February 2026—A study of 830 children with pediatric central nervous system tumors found that 23.3% carried germline pathogenic variants in cancer predisposition genes, impacting tumor development and outcomes. Another study identified pathogenic variants in 13.2% of infertile women experiencing IVF/ICSI failures, with TUBB8 being the most frequently mutated gene.

Q&A column

February 2026
Q. Why aren’t more medical students interested in applying for a pathology residency? Read answer.

Q. What is your opinion on employing qualitative rapid homogeneous immunoassay (enzyme-multiplied immunoassay technique, ELISA) urine screens for tricyclic antidepressant (TCA) testing in pregnant women and emergencies involving neonates, particularly at a low cutoff threshold of 300 ng/mL? Read answer.

Newsbytes

February 2026—Vega Health, founded by Dr. Mark Sendak, aims to democratize AI-based healthcare solutions by providing small to mid-sized health systems with access to proven AI innovations developed by healthcare professionals.

Put It on the Board

February 2026—The CAP supports the FDA’s proposal to reclassify oncology therapeutic nucleic-acid-based test systems from class III to class II devices with 510(k) requirements.

MARKETPLACE

TRENDING